Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been assigned an average rating of “Moderate Buy” from the eighteen analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $60.4706.

A number of equities research analysts recently issued reports on RARE shares. Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. HC Wainwright dropped their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. The Goldman Sachs Group cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and dropped their price target for the company from $61.00 to $25.00 in a research note on Tuesday, March 24th. Leerink Partners dropped their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Finally, Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president owned 76,346 shares of the company’s stock, valued at $1,740,688.80. The trade was a 9.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Theodore Alan Huizenga sold 1,632 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $37,209.60. Following the sale, the chief accounting officer directly owned 48,670 shares in the company, valued at approximately $1,109,676. This trade represents a 3.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 109,556 shares of company stock worth $2,490,138 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. boosted its stake in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares during the last quarter. Huntington National Bank boosted its stake in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth $39,000. Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares during the last quarter. Finally, Covestor Ltd boosted its stake in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $23.15 on Friday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -3.96 and a beta of 0.25. Ultragenyx Pharmaceutical has a 12 month low of $18.29 and a 12 month high of $42.37. The firm’s 50 day simple moving average is $22.11 and its 200-day simple moving average is $27.64.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. During the same period in the prior year, the business posted ($1.39) EPS. Ultragenyx Pharmaceutical’s revenue was up 25.5% compared to the same quarter last year. Analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.